🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1er colloque français sur le cancer du poumon à mutations rares : INSPIRE à pleins poumons 📆 Paris – les 9 & 10 nov 🤝 Patients, aidants, experts réunis pour 2 jours d’échanges, de savoirs & de rencontres. 🎟️ Programme et Inscriptions : colloqueinspire.teamresa.net

🫁 Small Cell Lung Cancer (SCLC) faces major hurdles: 🔹 High heterogeneity 🔹 Phenotypic plasticity 🔹 Rapid resistance Molecular subtypes & DLL3-targeted therapy offer hope for tailored strategies. Nature Reviews Cancer 📖 doi.org/10.1038/s41568… #Oncology #SCLC #LungCancer

🔗 COALA project website is now live! 👉 coala-lung.org A national multidisciplinary consortium supported by the Institut national du cancer bringing together experts in lung cancer research to improve outcome of lung cancer patients with oncogenic addiction.

Bravo Benjamin Besse! Very welcome news. Looking forward to your Presidency

Can laughter help if you’re living with #lungcancer? Early research suggests it might improve mood & ease stress. Broader cancer studies show benefits for anxiety, fatigue & even pain. Not a treatment. But it might make a tough day a little lighter. Sources: European Lung Foundation &

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

‼️ 1 week to go. Please help us make the 10th LuCE survey on #lungcancer & mental health our biggest yet. 📝 Open to anyone in Europe with lung cancer or caring for someone who does ⏱️ Takes 10 mins 🌍 Available in 19 languages 🔗 Take part: surveymonkey.com/r/LuCESurvey20… #LCSM

New publication alert‼️ frontiersin.org/journals/oncol…

Absolutely brilliant review from @NarjustFlorez 🌟 & team calling for change. A must read. Young people with lung cancer face: ▪️High rates of targetable mutations ▪️Delayed diagnosis ▪️Brain mets at presentation ▪️Exclusion from screening We need better screening, faster

Lung Cancer Europe - Lung Cancer Survival Has More Than Doubled Lung Cancer Europe oncodaily.com/science/lung-c… #Cancer #CancerResearch #LungCancer #LCSM #LuCE #HealthEquity #MedX #MedNews #MedEd #AccessToCare #PrecisionMedicine #Medicine #Health #Oncology #OncoDaily

Last week, 4 #lungcancer advocates from LuCE member organisations took part in WECAN Academy 2025 - a European training programme for cancer advocacy. From HTA to clinical trials to the lived reality of pushing for better access, it was a full-on few days of learning,

📢Silence is Complicity!! In this The ASCO Post article, Coral Olazagasti, MD & Narjust Florez, MD, FASCO raise the alarm on Executive Order 14151 and its damaging effects on DEI, cancer research, and health equity. 📎 ascopost.com/issues/june-25…

The journey from resident or fellow to a board-certified attending oncologist is a multifaceted and often daunting endeavor. Eric K. Singhi, MD Nicholas Hornstein Marc Braunstein, MD, PhD, FACP Nerea Lopetegui-Lia, MD MinhTri Nguyen, MD (he/him) cancernetwork.com/view/navigatin…

Excited to share our IASLC paper: 🧭 “50 Years of Progress in #NSCLC” JTO & JTO CRR A review of breakthroughs in #LungCancer—from chemo to targeted therapy to #immunotherapy ! 🔗 bit.ly/44wRj6w OncoAlert LungCancerRx 🫁💊 Oncology Brothers Hem-Onc Fellows Network UAB O'Neal Comprehensive Cancer Center

As a thoracic oncologist, I have seen hundreds of patients with lung cancer (NSCLC and SCLC) being treated under standard of care or a clinical trial (my passion). Lung cancer therapies significantly started to expand in the early 2010s. In recent weeks, we have had several

People with #lungcancer & low BMI are more likely to develop brain metastases - a link not seen in other cancers. New open access study in Nature Communications, July 2025. Researchers suggest it’s driven by brain signalling changes, not just weight loss. 🔗

Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

In Aug ’21, I was unwell, had 2 biopsies & waited weeks for answers. A liquid biopsy trial gave me an ALK+ #lungcancer diagnosis in 10 days. Now NHS England is rolling this out! 🎙️ Alastair Greystoke & I spoke w Roy Castle Lung Cancer Foundation on this & more: 👉 roycastle.org/our-support/po… #LCSM

Have you caught up on Episode 1 of LungCancerRx 🫁💊 yet? Your refill is almost due… because Episode 2 drops NEXT WEEK! 🎧💥 Oncology News Central Eric K. Singhi, MD Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Jill Feldman